MetaVia Inc(MTVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MTVA MetaVia Inc

Post-Mkt 05-19 19:45:03 EDT

1.88

+0.77

+69.37%

盘后2.04

+0.16+8.52%

19:44 EDT

High2.10	Low1.53	Vol84.97M
Open1.80	D1 Closing1.11	Amplitude51.35%
Mkt Cap9.71M	Tradable Cap6.23M	Total Shares5.16M
T/O160.55M	T/O Rate2,564.57%	Tradable Shares3.31M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MTVA","market":"US","secType":"STK","nameCN":"MetaVia Inc","latestPrice":1.88,"timestamp":1779220800000,"preClose":1.11,"halted":0,"volume":84969421,"hourTrading":{"tag":"盘后","latestPrice":2.0402,"preClose":1.88,"latestTime":"19:44 EDT","volume":1175558,"amount":2217879.7845054003,"timestamp":1779234298044,"change":0.1602,"changeRate":0.085213,"amplitude":0.148936},"delay":0,"changeRate":0.6936936936936935,"floatShares":3313200,"shares":5164400,"eps":-2.541,"marketStatus":"Post-Mkt","change":0.77,"latestTime":"05-19 19:45:03 EDT","open":1.795,"high":2.1,"low":1.53,"amount":160545863.36778662,"amplitude":0.513514,"askPrice":2.05,"askSize":8221,"bidPrice":2.04,"bidSize":302,"shortable":3,"etf":0,"ttmEps":-2.541,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1779235200000},"marketStatusCode":4,"adr":0,"listingDate":1470369600000,"exchange":"NASDAQ","adjPreClose":1.11,"preHourTrading":{"tag":"盘前","latestPrice":1.79,"preClose":1.11,"latestTime":"09:29 EDT","volume":18808652,"amount":36209231.885324,"timestamp":1779197399999,"change":0.68,"changeRate":0.612613,"amplitude":0.918919},"postHourTrading":{"tag":"盘后","latestPrice":2.0402,"preClose":1.88,"latestTime":"19:44 EDT","volume":1175558,"amount":2217879.7845054003,"timestamp":1779234298044,"change":0.1602,"changeRate":0.085213,"amplitude":0.148936},"volumeRatio":959.005491},"requestUrl":"/m/hq/s/MTVA/tweets","defaultTab":"tweets","newsList":[{"id":"2636865778","title":"Sector Update: Healthcare Stocks Rise Tuesday Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2636865778","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636865778?lang=en_us&edition=fundamental","pubTime":"2026-05-20 02:02","pubTimestamp":1779213753,"startTime":"0","endTime":"0","summary":"Healthcare stocks rose Tuesday afternoon, with the NYSE Healthcare Index adding 1.1% and the State Street Healthcare Select Sector SPDR ETF (XLV) gaining 1.2%.The iShares Biotechnology ETF (IBB) incre","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B4R5TH58.HKD","LU0689472784.USD","LU0208291251.USD","JPMO","XLV","BK4585","LU2746668974.SGD","LU2505996509.AUD","LU0106261372.USD","XBI","IE00BWXC8680.SGD","LU0266013472.USD","LU2237443978.SGD","LU2265009873.SGD","LU0353189763.USD","IE00B1XK9C88.USD","IBB","LU2552382058.USD","TLSA","LABU","LU0640476718.USD","LU1057294990.SGD","BK4516","HCSG","LU2362541513.USD","IE0009355771.USD","LU1718418525.SGD","RLAY","LU0203347892.USD","BK4550","JPO","LU1670627923.USD","LU2491049909.HKD","LU0203345920.USD","LU1244550494.USD","BSX","LU2054465674.USD","LU0234572021.USD","BK4139","IE0034235295.USD","MTVA","LU0149725797.USD","BSX.AU","LU2023250843.SGD","LU2746668461.USD","LU1791710582.SGD","LU1989772840.SGD","IE00BJTD4N35.SGD","JPX","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636585391","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2636585391","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636585391?lang=en_us&edition=fundamental","pubTime":"2026-05-19 19:26","pubTimestamp":1779190011,"startTime":"0","endTime":"0","summary":"Amesite  shares were up 212% in Tuesday premarket trading after the company said it secured a new enterprise customer for its NurseMagic platform.Rubico  shares were 117% higher, recovering from a 6.5% decline on MondayMeiwu Technology  stock was 88% higher, recovering from Monday's 22% decline.MetaVia  shares were up 75% after the company said three late-breaking abstracts highlighting its cardiometabolic assets were accepted for poster presentations.Hub Cyber Security  stock was 18% higher, rebounding from Monday's 6.7% decline.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MTVA","BK4134","WNW","RUBI","BK4122","BK4139","BK4144","BK4204","AMST","BK4113","HUBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636407130","title":"MetaVia Price Target Maintained With a $20.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2636407130","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636407130?lang=en_us&edition=fundamental","pubTime":"2026-05-18 21:59","pubTimestamp":1779112740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MTVA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 18, 2026 09:59 ET (13:59 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636607589","title":"MetaVia presents Phase 1 higher-dose DA-1726 obesity data at ADA 2026 sessions","url":"https://stock-news.laohu8.com/highlight/detail?id=2636607589","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636607589?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:32","pubTimestamp":1779107524,"startTime":"0","endTime":"0","summary":"MetaVia flagged new Phase 1 higher-dose cohort results for its obesity drug candidate DA-1726, with data slated for presentation at the American Diabetes Association’s 2026 Scientific Sessions on June 7.The readout is positioned to clarify whether the dual GLP-1/glucagon program can support higher dosing with improved tolerability, a key step toward differentiation in the obesity market.Two additional late-breaking posters will present preclinical work on vanoglipel, pointing to potential synergy in combinations aimed at MASH and Type 2 diabetes.The conference disclosures set up a near-term catalyst cycle for the pipeline, with the company also targeting a separate update from an ongoing 16-week Phase 1 titration study in the fourth quarter.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDLbsMkt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635296907","title":"MetaVia Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635296907","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635296907?lang=en_us&edition=fundamental","pubTime":"2026-05-15 05:01","pubTimestamp":1778792467,"startTime":"0","endTime":"0","summary":"MetaVia Inc reports results for the quarter ended March 31 - Earnings SummaryMetaVia Inc MTVA.OQ reported a quarterly adjusted loss of 42 cents per share for the quarter ended March 31, higher than th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nL8N41R2JN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635267047","title":"MetaVia Q1 EPS $(0.79) Misses $(0.74) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635267047","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635267047?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:48","pubTimestamp":1778791696,"startTime":"0","endTime":"0","summary":"MetaVia (NASDAQ:MTVA) reported quarterly losses of $(0.79) per share which missed the analyst consensus estimate of $(0.74) by 6.76 percent. This is a 80.05 percent increase over losses of $(3.96) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52582906/metavia-q1-eps-0-79-misses-0-74-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"MetaVia Q1 EPS $(0.79) Misses $(0.74) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635725475","title":"MetaVia publishes investor presentation on obesity, MASH drug pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2635725475","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635725475?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:25","pubTimestamp":1778790317,"startTime":"0","endTime":"0","summary":"MetaVia investor deck highlighted lead obesity candidate DA-1726, a once-weekly GLP-1R/GCGR dual agonist, with Phase 1 multi-ascending dose data showing 9.1% weight loss at 48 mg by Day 54 with no titration.Same dataset showed 3.8-inch waist reduction, 0.22 HbA1c decline, 23.7% drop in liver stiffness , with mostly mild-to-moderate side effects.Program plan targets tolerability optimization with stepwise titration up to 64 mg, with Phase 1 Part 3 readout expected in Q4 2026.MASH asset vanoglipel , an oral GPR119 agonist, posted Phase 2a primary endpoint success in presumed MASH, with ALT down 22.8 U/L at Week 16, with significant HbA1c reductions at 100 mg versus placebo.Cash and cash equivalents were USD 13.7 million as of March 31, 2026, with no debt; capitalization table listed 5,164,370 common shares outstanding, 15,410,509 fully diluted.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDLTjSd1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635723052","title":"MetaVia Q1 net loss widens 4.1% to $3.82 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635723052","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635723052?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:14","pubTimestamp":1778789655,"startTime":"0","endTime":"0","summary":"Metavia posted a Q1 net loss of USD 3.82 million, widening from prior-year period, while loss per share narrowed to USD 0.79.Operating loss widened to USD 4.03 million as total operating expenses rose 3.6% to USD 4.03 million.Research and development spending fell 9.7% to USD 2.1 million, while general and administrative costs climbed 23.4% to USD 1.92 million.Cash and cash equivalents totaled USD 13.7 million at March 31, 2026; net cash used in operating activities was USD 4.26 million.DA-1726 Phase 1 Part 3a and 3b studies started in April 2026 with data readout planned for Q4 2026, while vanoglipel Phase 2a clinical study report is expected in first half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDLbbGJgK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635272380","title":"Metavia Reports First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635272380","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635272380?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:05","pubTimestamp":1778789103,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUA51XJYM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635723138","title":"Press Release: MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635723138","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635723138?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:05","pubTimestamp":1778789100,"startTime":"0","endTime":"0","summary":"48 mg Phase 1 Data Demonstrated Potential Best-in-Class Profile for DA-1726 with 9.1% Weight Loss, Improved Glucose Control and Direct Liver Benefit. Key Milestone Achieved with Dosing of the First Patient in Phase 1 Part 3 16-Week Titration Study Evaluating 48 mg  and 64 mg  Regimens; Data Expected in Fourth Quarter 2026. CAMBRIDGE, Mass., May 14, 2026 /PRNewswire/ -- MetaVia Inc. , a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the first quarter ended March 31, 2026, and provided a corporate strategic update.-- May 2026: Announced the presentation of additional data from the 48 mg. Phase 1 trial of DA-1726 at the EASL Congress 2026 in a poster entitled,an Oxyntomodulin Analogue, in a Higher-Dose Phase 1 Cohort with. -- April 2026: Dosed the first patient in Part 3 of the Phase 1 clinical. trial evaluating DA-1726 in obese, otherwise healthy adults, consisting. of two 16-week titration cohorts designed to ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","R","BK4202","MTVA","BK4022","OXM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634890642","title":"MetaVia highlights higher-dose Phase 1 DA-1726 data in EASL late-breaking poster","url":"https://stock-news.laohu8.com/highlight/detail?id=2634890642","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634890642?lang=en_us&edition=fundamental","pubTime":"2026-05-11 20:33","pubTimestamp":1778502804,"startTime":"0","endTime":"0","summary":"MetaVia flagged new Phase 1 higher-dose cohort data for obesity drug candidate DA-1726, a dual GLP-1/glucagon agonist, in a late-breaking poster accepted for EASL Congress 2026.Results have not yet been presented; poster is scheduled for May 27, 2026 in Barcelona.Readout is set to focus on safety, tolerability, drug exposure, pharmacodynamic activity, with an exploratory noninvasive liver assessment, positioning the program for dose optimization and potential differentiation in obesity.Company is running a 16-week Phase 1 Part 3 titration study to test higher dose levels and improve tolerability, with additional data expected in Q4 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL8qTRSy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634965498","title":"MetaVia Inc  expected to post a loss of 74 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2634965498","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634965498?lang=en_us&edition=fundamental","pubTime":"2026-05-09 06:57","pubTimestamp":1778281026,"startTime":"0","endTime":"0","summary":"MetaVia Inc  expected to post a loss of74cents a share - Earnings Preview MetaVia Inc MTVA.OQ MTVA.O is expected to  show no change in quarterly revenue when it reports  results on May 12 (estimated) ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L2VB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627237901","title":"MetaVia announces annual shareholder meeting webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2627237901","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627237901?lang=en_us&edition=fundamental","pubTime":"2026-04-16 04:02","pubTimestamp":1776283374,"startTime":"0","endTime":"0","summary":"MetaVia schedules virtual annual stockholder meeting for June 8, 2026.Vote set on election of two Class I directors to three-year terms ending at 2029 annual meeting.Ballot includes ratification of BDO USA as independent registered public accounting firm for fiscal 2026.Stockholders to consider reverse stock split within 1-for-5 to 1-for-22 range.Additional items include increasing 2022 Equity Incentive Plan share pool by 200,000 shares, with possible adjournment to seek more votes on reverse split or equity plan amendment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDL7bTQ3f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626190668","title":"MetaVia says first patient dosed in Part 3 of Phase 1 trial of DA-1726","url":"https://stock-news.laohu8.com/highlight/detail?id=2626190668","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626190668?lang=en_us&edition=fundamental","pubTime":"2026-04-10 20:36","pubTimestamp":1775824584,"startTime":"0","endTime":"0","summary":"MetaVia (MTVA) announced that the first patient has been dosed in Part 3 of its Phase 1 clinical trial evaluating DA-1726, a novel dual oxyntomodul...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/metavia-says-first-patient-dosed-in-part-3-of-phase-1-trial-of-da-1726-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/metavia-says-first-patient-dosed-in-part-3-of-phase-1-trial-of-da-1726-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626903771","title":"MetaVia doses first patient in higher-dose Phase 1 trial of obesity drug DA-1726","url":"https://stock-news.laohu8.com/highlight/detail?id=2626903771","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626903771?lang=en_us&edition=fundamental","pubTime":"2026-04-10 20:32","pubTimestamp":1775824337,"startTime":"0","endTime":"0","summary":"MetaVia dosed first patient in higher-dose Phase 1 study Part 3 for DA-1726, its dual GLP-1 and glucagon agonist for obesity.Program targets faster escalation to higher doses to improve tolerability, positioning drug for a more streamlined dosing path versus marketed options.Earlier Phase 1 data were already presented, showing meaningful weight loss and broader metabolic improvements without detailing technical measures.New results will be presented in fourth quarter 2026.Study plans to enroll 40 obese, otherwise healthy adults across two 16-week titration cohorts.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL42mxM8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626388190","title":"Metavia Inc - Data From Phase 1 Part 3 Trial Expected in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2626388190","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626388190?lang=en_us&edition=fundamental","pubTime":"2026-04-10 20:30","pubTimestamp":1775824200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nTUA5DDSKD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626197074","title":"Metavia Doses the First Patient in Higher-Dose Phase 1 Study of Da-1726, Its Glp-1 and Glucagon Dual Agonist for the Treatment of Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2626197074","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626197074?lang=en_us&edition=fundamental","pubTime":"2026-04-10 20:30","pubTimestamp":1775824200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nTUA5DDSKD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624482545","title":"MetaVia (MTVA): Differentiated Dual-Agonist Obesity Therapy and Solid Cash Runway Underpin Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2624482545","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624482545?lang=en_us&edition=fundamental","pubTime":"2026-04-02 00:45","pubTimestamp":1775061923,"startTime":"0","endTime":"0","summary":"MetaVia, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim Group maintained a Buy ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/metavia-mtva-differentiated-dual-agonist-obesity-therapy-and-solid-cash-runway-underpin-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/metavia-mtva-differentiated-dual-agonist-obesity-therapy-and-solid-cash-runway-underpin-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622879165","title":"MetaVia Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2622879165","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622879165?lang=en_us&edition=fundamental","pubTime":"2026-03-28 00:37","pubTimestamp":1774629420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MTVA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 27, 2026 12:37 ET (16:37 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622994258","title":"MetaVia publishes investor presentation; outlines obesity and MASH pipeline, cash and cash equivalents $10.3 million as of Dec. 31, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2622994258","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622994258?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:41","pubTimestamp":1774557719,"startTime":"0","endTime":"0","summary":"MetaVia publishes investor presentation; outlines obesity and MASH pipeline, cash and cash equivalents $10.3 million as of Dec. 31, 2025. MetaVia outlined a cardiometabolic pipeline focused on obesity and metabolic dysfunction-associated steatohepatitis , highlighting DA-1726 and vanoglipel .For DA-1726, the company reported -9.1% body weight and -23.7% liver stiffness at Day 54 at a 48 mg dose.MetaVia said DA-1726 Phase 1 Part 3 is evaluating stepwise titration up to 64 mg, with data expected by YE 2026.For vanoglipel, MetaVia said a Phase 2a study in presumed MASH met its primary endpoint and reported ALT reduction of 22.8 U/L.MetaVia reported cash and cash equivalents of USD 10.3 million and no debt as of December 31, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as f","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL3Ynvsd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.metaviatx.com","stockEarnings":[{"period":"1week","weight":0.0673},{"period":"1month","weight":-0.2071},{"period":"3month","weight":-0.2792},{"period":"6month","weight":-0.8679},{"period":"1year","weight":-0.8526},{"period":"ytd","weight":-0.8682}],"compareEarnings":[{"period":"1week","weight":-0.0009},{"period":"1month","weight":0.0401},{"period":"3month","weight":0.0817},{"period":"6month","weight":0.1147},{"period":"1year","weight":0.2431},{"period":"ytd","weight":0.0832}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.000503},{"month":2,"riseRate":0.3,"avgChangeRate":0.007282},{"month":3,"riseRate":0.5,"avgChangeRate":-0.031121},{"month":4,"riseRate":0.4,"avgChangeRate":-0.109498},{"month":5,"riseRate":0.2,"avgChangeRate":-0.12128},{"month":6,"riseRate":0.555556,"avgChangeRate":0.090563},{"month":7,"riseRate":0.222222,"avgChangeRate":-0.026489},{"month":8,"riseRate":0.222222,"avgChangeRate":-0.189997},{"month":9,"riseRate":0.4,"avgChangeRate":0.065402},{"month":10,"riseRate":0.2,"avgChangeRate":-0.186131},{"month":11,"riseRate":0.3,"avgChangeRate":-0.112358},{"month":12,"riseRate":0.1,"avgChangeRate":-0.160075}],"exchange":"NASDAQ","name":"MetaVia Inc","nameEN":"MetaVia Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MetaVia Inc(MTVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest MetaVia Inc(MTVA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"MetaVia Inc,MTVA,MetaVia Inc股票,MetaVia Inc股票老虎,MetaVia Inc股票老虎国际,MetaVia Inc行情,MetaVia Inc股票行情,MetaVia Inc股价,MetaVia Inc股市,MetaVia Inc股票价格,MetaVia Inc股票交易,MetaVia Inc股票购买,MetaVia Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MetaVia Inc(MTVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest MetaVia Inc(MTVA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}